AVR 2.79% $10.11 anteris technologies ltd

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-33

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,918 Posts.
    lightbulb Created with Sketch. 59
    An EFS - Early Feasibility Study - would be a small number:
    So sayeth the FDA

    A Pivotal study for a Medical Device would be analogous to a Phase-3 drug trial. Just what size patient cohort would be required I couldn't say.
    My mug's eye view would be that 500 would be the low end of a Pivotal Study.

    Informed opinions about plausible sequences to commercialsation welcomed.

    P
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
(20min delay)
Last
$10.11
Change
-0.290(2.79%)
Mkt cap ! $217.9M
Open High Low Value Volume
$10.57 $10.59 $9.90 $137.7K 13.38K

Buyers (Bids)

No. Vol. Price($)
3 133 $10.03
 

Sellers (Offers)

Price($) Vol. No.
$10.19 1077 2
View Market Depth
Last trade - 14.06pm 07/11/2024 (20 minute delay) ?
AVR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.